Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;1(4):e14.
doi: 10.1038/bcj.2011.13. Epub 2011 Apr 1.

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo

M Yu, E J Gang, R Parameswaran, S Stoddart, F Fei, S Schmidhuber, E Park, Y T Hsieh, A S Yang, J Groffen, N Heisterkamp, Y M Kim

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo

M Yu et al. Blood Cancer J. 2011 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Combination therapy using AMD3100 and nilotinib prolongs survival of murine ALL transplant recipients. C57Bl mice transplanted with 104 Bcr/Abl P190 ALL 8093 cells were allowed to develop full leukemia within 11–17 days. (a) Fold increase 2 h after injection in percentage CD45.1+ or CD45.2+ cells in peripheral blood with respect to percentage before injection with phosphate-buffered saline (PBS) or AMD3100 in the same animal (n=3 per group). (b) White blood cells on day 17 after transplant (treatment day 1), before and after injection with PBS or before and after injection with 10 mg/kg AMD3100 (n=3 mice per group). Mice then received a daily injection with PBS or AMD3100 for 9 more days. On treatment day 10, white blood cells sampling, before and 2 h after injection, was repeated. *P<0.05, paired Student's t-test. (c) Leukemic transplanted mice were treated with PBS, nilotinib/AMN107 (60 mg/kg per d p.o.), AMD3100 (10 mg/kg per d i.p.) or nilotinib+AMD3100 (n=6 per group). Nilotinib+AMD3100 versus nilotinib P=0.047, log-rank test.
Figure 2
Figure 2
Preclinical evaluation of AMD3100 as an adjuvant treatment for human drug-resistant ALL. (a) Mobilization of human ALL cells. At 12 days after transplant of human pre-B ALL 697 (6 × 106 cells/mouse) NOD/SCID/IL2Rγ−/− mice were injected i.p. with phosphate-buffered saline (n=3) or AMD3100 (30 mg/kg) (n=3). White blood cells (top) or human CD19+ cells in peripheral blood (bottom) at 2 h after injection. *P<0.05, paired Student's t-test. (b) Survival of NOD/SCID/IL2Rγ−/− mice engrafted with primary ALL (US7R) cells and treated with saline (circles, n=2), VDL (vincristine 0.5 mg/kg per d, dexamethasone 10.5 mg/kg per d, -asparaginase 1500 IU/kg per day) (triangles up, n=3), AMD3100 (10 mg/kg per day) (squares, n=3) or VDL plus AMD3100 (triangle down, n=6) for 28 days. AMD3100 was administered via a subcutaneous mini-osmotic pump. VDL+AMD3100 versus VDL, P=0.015, log-rank test.
See this image and copyright information in PMC

References

    1. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201:1307–1318. - PMC - PubMed
    1. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia. 2003;7:1294–1300. - PubMed
    1. Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia. 2007;6:1249–1257. - PubMed
    1. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res. 2006;66:5387–5393. - PubMed
    1. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206–6214. - PMC - PubMed